Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

BACKGROUND: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination of treatment. However, we treated two patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitawaki, Tatsuya, Sakata, Yoshihiko, Kawamura, Kodai, Ichikado, Kazuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718064/
https://www.ncbi.nlm.nih.gov/pubmed/29207989
http://dx.doi.org/10.1186/s12890-017-0519-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718064/
https://www.ncbi.nlm.nih.gov/pubmed/29207989
http://dx.doi.org/10.1186/s12890-017-0519-y

Ejemplares similares